Journal of Endocrinology and Metabolism, ISSN 1923-2861 print, 1923-287X online, Open Access
Article copyright, the authors; Journal compilation copyright, J Endocrinol Metab and Elmer Press Inc
Journal website https://www.jofem.org

Original Article

Volume 11, Number 2, April 2021, pages 42-48


The Significance of Insulin Resistance in Nondiabetic Breast Cancer Patients

Tables

Table 1. Demographic and Biochemical Parameters of the Groups
 
Control group (n = 60)Breast cancer (n = 80)P
BMI: body mass index; FBG: fasting blood glucose; FIL: fasting insulin level; HbA1c: hemoglobin A1c; HOMA-IR: homeostasis model assessment-insulin resistance; TNM: tumor-node-metastasis; ER: estrogen receptor; PR: progesterone receptor; HER-2/neu: human epidermal growth factor receptor-2.
Age (years)49.8 ± 11.550.4 ± 12.50.750
BMI (kg/m2)25.67 ± 1.4325.79 ± 1.480.567
FIL (mIU/L)7.1 ± 1.716.5 ± 3.7< 0.001
FBG (mg/dL)89.9 ± 8.593.8 ± 10.30.099
HbA1c (%)5.3 ± 0.45.2 ± 0.30.815
HOMA-IR1.57 ± 0.454.81 ± 1.19< 0.001
TNM
  18 (10)
  223 (28.7)
  322 (27.5)
  427 (33.8)
ER
  Negative28 (35)
  Positive52 (65)
PR
  Negative44 (55)
  Positive36 (45)
HER-2
  Negative61 (76.3)
  Positive19 (23.8)
Classification
  Triple (-)3 (3.8)
  Luminal46 (57.5)
  HER-2 (+)19 (23.8)
  Triple (+)12 (15)

 

Table 2. Demographic and Biochemical Parameters of the Groups for Menopause
 
Control groupBreast cancer
Premenopause (n = 30)Menopause (n = 30)PPremenopause (n = 40)Menopause (n = 40)P
Comparison with control group, *P < 0.001. BMI: body mass index; FBG: fasting blood glucose; FIL: fasting insulin level; HbA1c: hemoglobin A1c; HOMA-IR: homeostasis model assessment-insulin resistance.
Age (years)39.1 ± 3.160.5 ± 4.5< 0.00138.9 ± 4.061.9 ± 5.4< 0.001
BMI (kg/m2)25.46 ± 1.2425.88 ± 1.570.50125.76 ± 1.4625.82 ± 1.500.558
FIL (mIU/L)7.1 ± 1.57 ± 1.80.99216.8 ± 3.9*16.2 ± 3.4*0.712
FBG (mg/dL)88.3 ± 18.691.7 ± 8.50.87590.2 ± 9.895.6 ± 11.20.546
HbA1c (%)5.2 ± 0.45.4 ± 0.30.7525.1 ± 0.45.3 ± 0.30.999
HOMA-IR1.54 ± 0.481.59 ± 0.430.7884.81 ± 1.18*4.82 ± 1.21*0.995

 

Table 3. Sensitivity, Specificity, AUC, Cutoff, and Asymptotic Significance of Parameters in Study Groups (Control vs. Breast Cancer)
 
Sensitivity (%)Specificity (%)AUCCutoffP
FIL: fasting insulin level; HOMA-IR: homeostasis model assessment-insulin resistance; AUC: area under the curve.
FIL (mIU/L)98.882.70.9878.5< 0.001
HOMA-IR97.596.70.9982.4< 0.001

 

Table 4. Biochemical Parameters of the Breast Cancer Group for TNM Stage
 
TNMP
1234
FIL: fasting insulin level; HOMA-IR: homeostasis model assessment-insulin resistance; TNM: tumor-node-metastasis.
FIL (mIU/L)10.3 ± 1.414.9 ± 3.417.4 ± 2.219 ± 2.2< 0.001
HOMA-IR2.7 ± 0.44.1 ± 0.75.1 ± 0.75.9 ± 0.6< 0.001

 

Table 5. Biochemical Parameters of the Breast Cancer Group for ER, PR and HER-2
 
PR (-), (n = 44)PR (+), (n = 36)P
FIL: fasting insulin level; HOMA-IR: homeostasis model assessment-insulin resistance; ER: estrogen receptor; PR: progesterone receptor; HER-2/neu: human epidermal growth factor receptor-2.
FIL (mIU/L)16.3 ± 3.916.7 ± 3.40.645
HOMA-IR4.8 ± 1.34.9 ± 1.10.616
ER (-), (n = 28)ER (+), (n = 52)P
FIL (mIU/L)16.7 ± 3.816.4 ± 3.60.767
HOMA-IR4.9 ± 1.24.8 ± 1.20.556
HER-2 (-), (n = 61)HER-2 (+), (n = 19)P
FIL (mIU/L)16.2 ± 3.617.6 ± 3.80.127
HOMA-IR4.7 ± 1.25.2 ± 1.10.115